| 摘要 |
PROBLEM TO BE SOLVED: To obtain the subject inhibitor containing activated carbon as an active ingredient, inhibiting the expression of transforming growth factor-β, metalloprotease tissue inhibitor and collagen and useful for treating and preventing diseases exhibiting the disease states of extracellular matrix formation sthenia and fiberization sthenia. SOLUTION: This inhibitor contains activated carbon, preferably spherical activated carbon, as an active ingredient. The spherical activated carbon preferably has a diameter of 0.1-1 mm, a specific surface area of 700-1,500 m<2> /g, a fine pore radius of 100-75,000Åand a porosity of 0.05-0.8 ml/g. The spherical activated carbon includes granulated spherical activated carbon obtained from carbonaceous powder, spherical activated carbon obtained by calcining an organic polymer and spherical activated carbon originating from a petroleum- based hydrocarbon (petroleum-based pitch). The inhibitor is preferably orally administered. The inhibitor is administered at a daily dose of 0.2-20 g (as the amount of the spherical activated carbon) with one or several portions for a human adult.
|
